Study of VIR-5500 for advanced prostate cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to other parts of the body (based on scans like CT, MRI, or bone scan).
- Your cancer is growing despite past treatments, shown by rising PSA or new spots on scans.
- You have already tried at least one newer hormone therapy (like abiraterone, enzalutamide) and one type of chemotherapy (like docetaxel).
- Your cancer is castration-resistant (still growing even when testosterone is very low).
- You are not able to receive or have already tried standard care options for your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests an investigational drug called KMV002 in men with prostate cancer that has spread to other parts of the body and is no longer controlled by hormone therapy. The goal is to see if the drug can help slow or stop the cancer.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
Hear when a new Hormone-refractory Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.